Oral 9-cis retinoic acid (Alitretinoin) in the treatment of myelodysplastic syndromes: results from a pilot study
暂无分享,去创建一个
A. Ganser | P. Fenaux | C. Chomienne | C. Kowal | D. Hoelzer | A. Burnett | S. Castaigne | W. Hofmann | W. Kell | R. Burnett
[1] G. Mufti,et al. Apoptosis and its significance in MDS: controversies revisited. , 1999, Leukemia research.
[2] H P Koeffler,et al. Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro. , 1999, Blood.
[3] W. Hofmann,et al. Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes. , 1999, Experimental hematology.
[4] A. Ganser,et al. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor , 1999, Annals of Hematology.
[5] N. Komatsu,et al. Dominant negative effect of a truncated erythropoietin receptor (EPOR-T) on erythropoietin-induced erythroid differentiation: possible involvement of EPOR-T in ineffective erythropoiesis of myelodysplastic syndrome. , 1999, Experimental hematology.
[6] S. Soignet,et al. Clinical study of 9-cis retinoic acid (LGD1057) in acute promyelocytic leukemia , 1998, Leukemia.
[7] V. Santini,et al. DIFFERENTIATION THERAPY OF MYELODYSPLASTIC SYNDROMES: FACT OR FICTION? , 1998, British journal of haematology.
[8] J. Marshall,et al. Phase I study of 9-cis-retinoic acid (ALRT1057 capsules) in adults with advanced cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[9] Parker,et al. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes , 1998, British journal of haematology.
[10] Y Yoshida,et al. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. , 1998, Haematologica.
[11] T Hamblin,et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. , 1997, Blood.
[12] L. Hoefsloot,et al. Erythropoietin-induced activation of STAT5 is impaired in the myelodysplastic syndrome. , 1997, Blood.
[13] A. Ganser,et al. Clinical use of hematopoietic growth factors in the myelodysplastic syndromes. , 1997, Leukemia & lymphoma.
[14] A. Pileri,et al. Combined differentiating therapy for myelodysplastic syndromes: a phase II study. , 1996, Leukemia research.
[15] A. Ganser,et al. Myelodysplastic syndromes: clinical features. , 1996, Seminars in hematology.
[16] H. Koeffler,et al. Differentiation therapy in myelodysplastic syndromes. , 1996, Seminars in hematology.
[17] A. Ganser,et al. Improved multilineage response of hematopoiesis in patients with myelodysplastic syndromes to a combination therapy with all-trans-retinoic acid, granulocyte colony-stimulating factor, erythropoietin and α-tocopherol , 1996, Annals of Hematology.
[18] M. Kris,et al. Initial clinical trial of the retinoid receptor pan agonist 9-cis retinoic acid. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[19] M. Asaka,et al. All-Trans Retionic ACid in the Treatment of Myelodysplastic Syndromes , 1995 .
[20] D. Bowen. What is ineffective erythropoiesis in myelodysplastic syndromes? , 1995, Leukemia & lymphoma.
[21] P. Chambon,et al. Developmental roles of the retinoic acid receptors , 1995, The Journal of Steroid Biochemistry and Molecular Biology.
[22] T. Martin,et al. Regulation and regulatory role of the retinoids. , 1995, Critical reviews in eukaryotic gene expression.
[23] C. Finelli,et al. All-trans retinoic acid in the treatment of myelodysplastic syndromes. , 1995, Leukemia & lymphoma.
[24] D. Mangelsdorf,et al. Vitamin A receptors. , 2009, Nutrition reviews.
[25] W. Bollag. Experimental basis of cancer combination chemotherapy with retinoids, cytokines, 1,25‐dihydroxyvitamin D3, and analogs , 1994, Journal of cellular biochemistry.
[26] K. Sawada,et al. Impaired proliferation and differentiation of myelodysplastic CD34+ cells. , 1994, Leukemia & lymphoma.
[27] A. Ganser,et al. Effect of combination therapy with all-trans-retinoic acid and recombinant human granulocyte colony-stimulating factor in patients with myelodysplastic syndromes. , 1994, Leukemia.
[28] Pemrick Sm,et al. The retinoid receptors. , 1994 .
[29] H. Koeffler,et al. Effects of novel retinoic acid compound, 9-cis-retinoic acid, on proliferation, differentiation, and expression of retinoic acid receptor-alpha and retinoid X receptor-alpha RNA by HL-60 cells. , 1993, Blood.
[30] N. Gattermann,et al. All-trans retinoic acid in patients with myelodysplastic syndromes: results of a pilot study. , 1993, Blood.
[31] A. Ganser,et al. Induction of TNF‐α in patients with myelodysplastic syndromes undergoing treatment with interleukin‐3 , 1993, British journal of haematology.
[32] H. Stunnenberg. Mechanisms of transactivation by retinoic acid receptors , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.
[33] H. Koeffler,et al. 9-cis-retinoic acid : effects on normal and leukemic hematopoiesis in vitro , 1993 .
[34] R. Warrell,et al. Clinical pharmacology of oral all-trans retinoic acid in patients with acute promyelocytic leukemia. , 1992, Cancer research.
[35] H. Koeffler,et al. Differentiation-inducing agents in the treatment of myelodysplastic syndromes. , 1992, Seminars in oncology.
[36] K. Umesono,et al. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling , 1992, Nature.
[37] Gregor Eichele,et al. 9-cis retinoic acid is a high affinity ligand for the retinoid X receptor , 1992, Cell.
[38] J. Grippo,et al. 9-Cis retinoic acid stereoisomer binds and activates the nuclear receptor RXRα , 1992, Nature.
[39] G. Morriss-Kay. Retinoic acid receptors in normal growth and development. , 1992, Cancer surveys.
[40] Christine Chomienne,et al. The PML-RARα fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR , 1991, Cell.
[41] P. Nowell,et al. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alpha-tocopherol. , 1990, The American journal of medicine.
[42] E. Kimby,et al. Treatment of myelodysplastic syndromes with retinoic acid and 1α‐hydroxy‐vitamin D3 in combination with low‐dose ara‐C is not superior to ara‐C alone. Results from a randomized study , 1990 .
[43] Christine Chomienne,et al. The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus , 1990, Nature.
[44] R. Evans,et al. Nuclear receptor that identifies a novel retinoic acid response pathway , 1990, Nature.
[45] E. Kimby,et al. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). , 1990, European journal of haematology.
[46] G. Gahrton,et al. Therapeutic effects of low‐dose cytosine arabinoside, alpha‐interferon, 1α‐hydroxyvitamin D3 and retinoic acid in acute leukemia and myelodysplastic syndromes , 1988, European journal of haematology.
[47] D. Heitjan,et al. Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. , 1988, Blood.
[48] Pierre Chambon,et al. A human retinoic acid receptor which belongs to the family of nuclear receptors , 1987, Nature.
[49] H. Gralnick,et al. Proposals for the classification of the myelodysplastic syndromes , 1982, British journal of haematology.